Ipsum Diagnostics

Ipsum Diagnostics operates as a CAP-accredited and CLIA-certified high-complexity national reference laboratory. It provides rapid molecular diagnostic services for infectious diseases using PCR technology and offers anatomical pathology services. The company developed a COVID‑19 PCR test that received FDA Emergency Use Authorization in early pandemic response. Its panels cover bacterial/wound pathogens, onychomycosis, comprehensive fungal detection, respiratory pathogens, urinary/genital tract infections; blood/toxicology/NGS panels are planned for the future. The lab serves specialties including neurology, dermatology, podiatry and more with personalized case review by expert clinicians. No clinical trial results are reported as it does not develop therapeutics.